Seattle Genetics Inc., of Bothell, Wash., reported U.S. and Canadian sales of Adcetris (brentuximab vedotin), its antibody-drug conjugate targeting CD30 for lymphoma, totaling $159 million for the second quarter, marking a 30% increase over net sales in the second quarter of 2018 and topping consensus estimates by roughly 7%.